Patient satisfaction with laser therapy

The value of laser therapy in BPH

Benign prostatic hyperplasia (BPH) is characterised by the development of lower urinary tract symptoms (LUTS), including voiding and storage problems, and has an increasing incidence in men over the age of 50 years.^1,2 In the past, transurethral resection of the prostate (TURP) was considered the standard of care surgical treatment.³ However, due to an increasing recognition that a singular approach may not fit all patients, alternative therapy methods have been on the rise, including laser therapy.³

Our laser therapy portfolio has the ability to deliver benefits to your patients in three key areas:

1.
Durable efficacy

2.
Technological advancements

3.
Patient satisfaction

Durable efficacy

Photoselective vaporisation of the prostate (PVP) using the GreenLight XPS^TM Laser Therapy System has been shown to be effective for the surgical management of benign prostatic obstruction in patients with large prostate volumes (>80 mL), resulting in positive perioperative and early post-operative outcomes.⁴

In the long term, PVP therapy has also been shown to maintain its efficacy. Prostate-specific antigen (PSA) level has been shown to decrease significantly with levels falling by 56% (2.0 ng/mL) at 3 months and a further 2.6 ng/mL reduction at 57 months.⁵

In addition, PVP with the GreenLight XPS is an effective technique able to durably improve reported clinical outcomes in patients with benign prostatic enlargement (BPE).⁵

Technological advancements

Compared to TURP, laser therapy has been proven to have shorter hospitalisation and catheterisation times,⁶ with one study reporting median catheterisation times of 22 hours versus 46.7 hours, respectively.⁷

At Boston Scientific, we continue to improve and develop our laser treatment portfolio. The GreenLight XPS Laser Therapy System has advanced technical specifications compared to previous devices, with a maximum power of 180 W and an improved beam geometry of the MoXy^TM fiber.⁸